Tag Archives: ACADIA Pharmaceuticals

Oppenheimer Gives a Hold Rating to ACADIA Pharmaceuticals (ACAD)

In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $42.00. The company’s shares closed last Wednesday at $42.87. According to TipRanks.com, Olson has currently

ACADIA Pharmaceuticals (ACAD) Gets a Hold Rating from Canaccord Genuity

In a report issued on July 31, Sumant Kulkarni from Canaccord Genuity maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $29.00. The company’s shares closed last Monday at $44.33. According to TipRanks.com,

ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from Needham

In a report released today, Alan Carr from Needham assigned a Buy rating to ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $60.00. The company’s shares closed last Tuesday at $44.84. According to TipRanks.com, Carr is a

Oppenheimer Remains a Hold on ACADIA Pharmaceuticals (ACAD)

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $48.00. The company’s shares closed last Friday at $52.23, close to its 52-week high of

Cantor Fitzgerald Believes ACADIA Pharmaceuticals (NASDAQ: ACAD) Still Has Room to Grow

In a report released today, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $63.00. The company’s shares closed last Thursday at $49.34, close to its 52-week high

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Globus Medical (NYSE: GMED) and Zynerba Pharmaceuticals (NASDAQ: ZYNE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ACADIA Pharmaceuticals (ACAD – Research Report), Globus Medical (GMED – Research Report) and Zynerba Pharmaceuticals (ZYNE – Research Report). ACADIA Pharmaceuticals (ACAD) Needham analyst Alan